Novartis announces positive phase III results for MS drug siponimod

ZURICH (Reuters) – Novartis AG said a late-stage study showed its oral, once-daily BAF312, or siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis.

ZURICH (Reuters) – Novartis AG said a late-stage study showed its oral, once-daily BAF312, or siponimod, reduced the risk of disability progression in a severe form of multiple sclerosis.
Original Article